
TuHURA Biosciences Secures Patent for Delta Opioid Receptor Technology
The U.S. Patent and Trademark Office has granted TuHURA Biosciences patent protection for technology designed to reprogram the tumor microenvironment. By targeting Delta Opioid Receptors (DOR) on immunosuppressive cells, the company aims to prevent T cell exhaustion, a critical failure point in current cancer immunotherapies.


























